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Abstract
The pinna，an important component of the external ear, first appeared in mammals. It 
plays a vital role in collecting sounds, radiating heat and signaling mood. In humans, 
the most common ear defect is microtia with prevalence rates ranging from 0.83 to 
17.4 per 10,000 births. However, only a minority of genetic or environmental causes 
have been found to date. Domestic pigs have obvious diversity in pinna size, 
indicating a potential animal model for pinna deformity in humans. 
To identify causative mutations underlying pinna size, we performed a genome 
scan in a large scale White Duroc x Erhualian pig resource family, of which Erhualian 
has exceptionally large and floppy pinna and White Duroc has small and erect or 
semi-erect pinna. We mapped a 1% genome-wide QTL for pinna size to a 2 cM 
confidence interval around 58 cM on chromosome 7, which explained over 40% 
phenotypic variance. We further fine-mapped the QTL and finally identified that a 
missense mutation PPARD G32E could cause such major QTL effect on pinna size in 
pigs. This is the first time a novel function of PPARD on controlling pinna size has 
been found. After that, we continued to study the function of the causative mutation at 
the molecular level. 
We showed that the G32E substitution reduced ligand-dependent transcription 
activity of PPARD by transient transfection analysis. We hypothesized three 
underlying mechanisms, i.e. the substitution might alter (i) subcellular localization, (ii) 
ligand binding affinity, and/or (iii) ubiquitination according to function of the A/B 
domain of PPARs. To check whether the substitution altered subcellular localization, 
we mutated glycine 32 of wild-type PPARD into glutamic acid. Using 
immunofluorescence analysis, we observed that wild-type PPARD completely 
localized in nucleus whereas G32E mutant resided partly in cytosol in PK-15 cells 
and primary pinna-driven chondrocytes. To elucidate the effect of the substitution on 
subcellular localization, we analysed A/B domain deletion mutant and G32E mutant 
treated by leptomycin B, an inhibitor of CRM1 export protein. The A/B domain 
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deletion mutant totally localized in the nucleus, whereas cytosolic localization of the 
G32E mutant was blocked by leptomycin B. This indicated that G32E substitution 
provided A/B domain a novel function to promote CRM1-mediated nuclear PPARD 
export. By surface plasmon resonance technology, we detected binding affinity of 
GW0742 towards purified His-tagged wild-type and mutated PPARD. Equilibrium 
dissociation constant (KD) did not show significant distinction between wild-type 
PPARD and G32E mutant. We also found that ubiquitination at lysine (K) 16-18 in 
the A/B domain of PPARD can promote ligand-induced transcription activation. The 
G32E substitution prevented ubiquitination of PPARD and thereby reduced 
transcription activity comparable with the neighbouring K16-18R mutant. In 
summary, the G32E substitution is a loss-of-function mutation that reduces 
transcription activity of PPARD by promoting nuclear export and changing 
non-proteolytic ubiquitination. Corresponding to this, we found that overexpression of 
G32E mutant led to 4.1-fold reduction of the mRNA levels of β-catenin and 40% 
decrease of Wnt/β-catenin signaling with TCF/LEF reporter assay compared with 
wild-type treatment. As we known, Wnt/β-catenin pathway inhibited chondrocyte 
differentiation and SOX9 expression during skeletal development. Furthermore, 
inactivation of SOX9 in pinna chondrocyte progenitor cells - cranial neural crest 
(CNC) cells resulted in a complete absence of cartilages and endochondral bones 
derived from the CNC. It indicated a potential mechanism underlying the G32E 
substitution in PPARD causing an increased pinna size in pigs. 
In this thesis, we also studied an 18-bp indel in the 5’-untranslated region (UTR) 
of SOX9, which is an essential transcription factor in all chondrocyte development. 
We identified an 18-bp insertion/deletion (indel) in the 5’-UTR of SOX9 in three pig 
breeds−Laiwu, Bamei and Large White. The 18-bp fragment harbours a CRE half-site 
that can interact with a transcription factor CREB by mobility and supershift analyses. 
We found that the variant was located in a stable stem loop within the secondary 
structure of 5’-UTR using RNA-folding software. The 18-bp deletion altered the 
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secondary structure. By transient transfection analysis, we identified that the 18-bp 
was indispensable to the translation of SOX9. The deletion significantly reduced 
translation efficiency and caused mRNA destability. To determine whether the indel 
plays a physiological role in pinna development of pigs, we performed an association 
study in a White Duroc x Erhualian resource population. In this population, the indel 
was not associated with pinna size. 
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Zusammenfassung 
Die Ohrmuschel stellt eine wichtige Komponente des Aussenohrs dar und entwickelte 
sich evolutionär in der Klasse der Säugetiere. Die Ohrmuschel der Tiere ist neben 
ihrer Funktion als Schalltrichter auch wichtig zur Wärmeableitung und als 
Signalgeber der optischen Kommunikation. 
Die häufigste humane Ohrmuschelfehlbildung ist die Mikrotie deren Prävalenz 
0,83 bis 17,4 pro 10.000 Geburten beträgt. Allerdings sind die genetischen und 
umweltbedingten Einflüsse auf die Ausbildung dieser Dysplasie nur unzureichend 
bekannt.  
Die verschiedenen Hausschweinerassen zeigen eine große Diversität der 
Ohrmuschelgröße und bieten sich deshalb als Tiermodel für die humane 
Ohrmuschel-Mikrotie an. 
Um kausative genetische Varianten zu identifizieren, die die Ohrmuschelgröße 
bei Schweinen beeinflussen, wurde zunächst eine genomweite Kopplungsanalyse an 
Tieren einer White Duroc x Erhualian Ressourcenfamilie durchgeführt. Während die 
Tiere der Rasse White Duroc kleine und aufrechte Ohren haben, sind die Ohren der 
chinesischen Erhualian Schweine außerordentlich groß und hängen herab. Ein 
Quantitative Trait Locus wurde mit einem Konfidenzbereich von 2 cM in der Region 
um 58 cM auf Chromosom 7 kartiert. In einer weiteren Feinkartierung konnte eine 
sinnverändernde Mutation im PPARD Gen identifiziert werden, die zu einem 
Austausch von Glycin zu Glutaminsäure an Position 32 des Proteins führt (G32E) und 
einen Haupteffekt auf die Entwicklung der Ohrmuschelgröße haben könnte. Ein 
Effekt von PPARD auf die Größenentwicklung der Ohrmuschel war jedoch zuvor 
nicht beschrieben, deshalb wurden weitere Experimente zur Aufklärung des Effektes 
der Mutation auf molekularer Ebene angestellt. 
Durch Transfektionstudien konnte gezeigt werden, dass der G32E Austausch in 
der A/B Domäne zu einer reduzierten ligandenabhängigen Aktivität von PPARD als 
Transkriptionsfaktor führt. Aufgrund der Funktion der A/B Domäne der PPARs 
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wurden zunächst drei mögliche zugrundeliegende Mechanismen angenommen, die 
durch die Mutation verändert werden könnten: i) subzelluläre Lokalisation, ii) 
Ligandenaffinität und/oder iii) die Ubiquitierung der Domäne. Der Einfluss der 
Mutation auf die subzelluläre Lokalisation wurde mittels Immunfluoreszenzfärbungen 
von PK-15 und primären Ohrmuschelchondrozyten, die entweder das mutierte oder 
das Wildtypprotein exprimierten, untersucht. Es konnte gezeigt werden, dass das 
Wildtypprotein vollständig im Nukleus lokalisiert ist während das veränderte Protein 
teilweise im Zytosol zu finden war. Um den Effekt der Mutation auf die subzelluläre 
Lokalisation des Proteins aufzuklären, wurden die G32E exprimierenden Zellen sowie 
Zellen, die PPARD mit vollständig deletierter A/B Domäne exprimieren, mit 
Leptomycin B inkubiert. Während das Protein mit der deletierten A/B Domäne 
vollständig im Nukleus lokalisiert war, wurde durch die Zugabe von Leptomycin B, 
das das CRM1 Exportprotein blockiert, die zytosolische Lokalisation des G32E 
PPARD unterbunden. Der Austausch G32E führt also zu einer neuen Funktion der 
A/B Domäne, die zu einem durch das CRM1 vermittelten nukleärem Export führt. 
Mittels Plasmon-Resonanz Spektroskopie wurde die Bindungsaffinität von GW0742 
zu dem His-markierten Wildtyp und mutiertem PPARD analysiert. Die 
Gleichgewichts-Dissoziation-Konstante (KD) der beiden Proteine zeigte jedoch keine 
signifikanten Unterschiede. Außerdem wurde gefunden, dass die Ubiquitinierung der 
Lysine an den Positionen 16-18 der A/B Domäne die ligandeninduzierte Aktivierung 
von PPARD fördern können. Es konnte gezeigt werden, dass der G32E Austausch die 
Ubiquitinierung des PPARD verhindert und die Aktivität des Protein als 
Transkriptionsfaktor in gleichem Maße senkt wie die Mutation der benachbarten 
Lysine in Arginine. 
Zusammenfassend handelt es sich bei dem untersuchten G32E Austausch um eine 
Funktionsverlust-Mutation, die die Aktivität des PPARD als Transkriptionsfaktor 
reduziert indem sie den Export des Proteins aus dem Nukleus fördert. Dies geschieht 
durch die Veränderung des nicht-proteolytischen Ubiquitinierungssignals. Im 
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Einklang mit diesen Ergebnissen konnte gezeigt werden, dass die G32E Variante des 
PPARD Proteins zu einer 4,1-fachen Reduktion der mRNA Expression von β-Catenin 
und einer 40%igen Reduktion der Wnt/β-Catenin Signalübertragung zum TCF/LEF 
Rezeptor führte. Es ist bekannt, dass der Wnt/β-Catenin Signalweg die Chondrozyten 
Differenzierung sowie die Expression von SOX9 während der embryonalen 
Entwicklung inhibiert. Außerdem führt die Inaktivierung von SOX9 in den 
Vorläuferzellen der Chondrozyten - den Zellen der cranialen Neuralleiste – zur 
Abwesenheit von Knorpel und endochondralen Knochen. Auch dieser 
Zusammenhang deutet auf die Auswirkung der G32E Mutation des PPARD auf die 
Größe der Ohrmuschel beim Schwein hin. 
Des Weiteren wurde eine 18-bp Deletion in der 5’-untranslatierten Region des 
SOX9 Gens untersucht. Die Deletion konnte in den drei Schweinerassen Laiwu, 
Bamei und Large White nachgewiesen werden. Mittels Mobilitäts- und 
Supershift-Analysen wurde nachgewiesen, dass die Deletion eine Bindungsstelle des 
CREB Transkriptionsfaktors betrifft. Außerdem konnte mittels einer 
RNA-Sekundästruktur Analyse Software gezeigt werden, dass sich die Deletion in 
einer stabilen Haarnadelstruktur befindet. Dies weist auf eine Veränderung der 
DNA-Sekundärstruktur durch die Mutation hin. Durch transiente 
Transfektionsanalysen konnte dann auch gezeigt werden, dass die von der Deletion 
betroffenen 18 bp für die Expression des SOX9 unbedingt notwendig sind. Die 
Deletion reduzierte die Translationseffizienz signifikant und führte zu einer 
Destabilisierung der mRNA. In einer daraufhin durchgeführten Assoziationsstudie in 
der White Duroc x Erhualian Ressourcenpopulation konnte aber keine Assoziation 
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Abbreviations 
APOE Apolipoprotein E 
BCL6 B-cell CLL/lymphoma 6 
BMP5 Bone morphogenetic protein 5 
CRE cAMP response element 
CREB cAMP response element-binding protein 
CFA Canis lupus familiaris chromosomes  
cM Centimorgan 
CNS Central nervous system 
CRM1 Chromosome region maintenance protein 
CD4 Cluster of differentiation 4 
CI Confidence interval 
CYP7B1 Cytochrome P450, family 7, subfamily B, polypeptide 1 
UBC9 Ubiquitin carrier protein 9 
eQTL Expression quantitative trait lous 
EYA1 Eyes absent homolog 1 
FGF Fibrobalst growth factor 
FGFR1 Fibroblast growth factor receptor 1 
GABPα GA binding protein transcription factor, alpha 
GWAS Genome-wide association study 
GSC Goosecoid homeobox 
GDF11 Growth differentiation factor 11 
HDAC3 Histone deacetylase 3 
HOXA Homeobox A cluster 
HOXB Homeobox B cluster 
IBD Identical-by-descent 
IGF2 Insulin-like growth factor 2 
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IRF6 Interferon regulatory factor 6 
IFNγ Interferon-gamma 
LCORL Ligand dependent nuclear receptor corepressor-like 
LFD Low-fact diet 
MMP9 Matrix metallopeptidase 9 
MDM2 MDM2 oncogene, E3 ubiquitin protein ligase 
MSRB3 Methionine sulfoxide reductase B3 
MAPK Mitogen-activated protein kinase 
NCOR Nuclear receptor corepressor 
NR6A1 Nuclear receptor subfamily 6, group A, member 1 
PTHLH Parathyroid hormone-like hormone 
PIN1 Peptidylprolyl cis/trans isomerase, NIMA-interacting 1 
PPAR Peroxisome proliferator-activated receptor 
PPARA Peroxisome proliferator-activated receptor alpha 
PPARD Peroxisome proliferator-activated receptor delta 
PPARG Peroxisome proliferator-activated receptor gamma 
PPRE PPAR response element 
PTEN Phosphatase and tensin homolog 
PLAG1 Pleiomorphic adenoma gene 1 
PGC2 PPARG coactivator2 
PIAS Protein inhibitor of activated STAT 
PKCα Protein kinase C, alpha 
PDK1 Pyruvate dehydrogenase kinase, isozyme 1 
QTG Quantitative trait gene 
QTL Quantitative trait locus 
QTN Quantitative trait nucleotides 
QTT Quantitative trait transcript 
RBCK1 RanBP-type and C3HC4-type zinc finger containing 1 
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RGSs Regulator of G-protein signalings 
RXR Retinoid X receptor 
SIPL1 SHANK-interacting protein-like 1 
SIAH2 Seven in absentia homolog 2 
SIX5 Sine oculis-related homeobox 5 
SUMO Small ubiquitin-like modifier 
SOX9 SRY (sex determining region Y)-box 9 
SSC Sus scrofa chromosomes 
Timp3 TIMP metallopeptidase inhibitor 3 
Sp1 Trans-acting transcription factor 1 
TNFα Tumor necrosis factor alpha 
RAF1 Murine leukemia viral oncogene homolog 1 
WNT5A Wingless-related MMTV integration site 5A  
WIF1 WNT inhibitory factor 1 
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1 External ear: evolution, development, and genetics 
1.1 External ear 
The ear is an auditory organ that can convert sound waves from the outside world into 
nerve impulses that are then sent to the brain. The central nervous system in the brain 
then translates these impulses into a spoken language, or a bird song, and so on. 
Besides auditory perception, the ear also holds other functions, like heat radiation, 
sense of balance and external signals in mood. 
The ear consists of three sections: the external ear, the middle ear, and the inner 
ear. The external ear collects sound and directs it down the ear canal; the middle ear 
converts the sound waves into mechanical motion; and finally, the hair cells in the 
inner ear transform mechanical vibration into electrical impulses that are transmitted 
to the brain. The external ear includes an external auditory canal, an eardrum and a 
visible pinna that resides outside of the head. The eardrum, a membrane that separates 
the external ear from the middle ear, evolved gradually among reptiles, birds, and 
mammals, respectively. But the more sophisticated eardrum first appeared in 
mammals, which helped them to sense high-frequency vibration (reptiles, for example, 
can still only detect low-frequency sound waves) [1, 2]. Along with this change, the 
visible pinna developed as well, to capture and funnel these sounds more effectively 
[3]. To simplify the writing, in the following passage, the term “ear” will substitute 
for “pinna.” 
In order to better adapt to their environment, mammals have evolved an 
extraordinary variety of ear shapes and sizes. The animal with the largest ears is the 
African elephant. His ears developed large surface areas due to the extreme heat of his 
natural environment with scant amounts of shade to protect him. They act as shades, 
to keep the elephant’s overall body temperature regulated [4]. Similarly, animals 
located in hot areas around the world have much larger ears than those located in cold 
regions, such as the arctic fox. Some mammals, like antelopes and foxes, can turn 
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their ears in any direction, like aerials, for receiving sound without having to turn 
their heads. Some underwater and burrowing animals have very small ears as well. 
Large amphibious nutria has very short and rounded ear structures, for example. 
Marine mammals, like dolphins, whales and manatees, have no ears. 
When humans began to domesticate animals, some specific preferences were 
gradually bred into the species, and they display greater levels of morphological and 
behavioural diversity. The ear belongs to one type of these traits. There are a variety 
of different ears in more than 350 dog breeds worldwide. According to ear shape and 
size, they can be roughly classified into six types, including: prick, button, semi-prick, 
hanging, rose, and bat. Ears also have an obvious diversity in Chinese indigenous 
domestic pigs; for example, Erhualian, Hetao Large-ear, Jiaxing Black and Meishan 
have large and floppy ears; Hang, Jiangquhai, Laiwu and Lantang have medium-sized, 
floppy ears; Bama Xiang, Diannan Small-ear and Tibetan have small, erect or 
half-flicked ears. This preference sometimes is directly correlated with the local 
culture. For example, owners prefer to breed Erhualian pigs with large ears as a 
cultural significance, because, as the saying goes, “to have huge ears is a symbol of 
good luck and wealth” [5]. 
 
1.2 Growth and development of the external ear 
The ear is derived from the first and second pharyngeal cleft that develops into six 
rounded protuberances around the sixth week of gestation in a human fetus. These 
hillocks fold and gradually shift upwards and backwards to their final positions in the 
head [6]. After birth, a healthy human ear continues growing rather linearly 
throughout life. The ear grows rapidly until 8 or 10 years and then declines slowly 
from this point on. Men have ears with a significantly larger surface area than women. 
This sexual dimorphism appears to start during postnatal growth [7, 8]. A similar 
growth pattern is also observed in mice, indicating that ear size increases rapidly only 
throughout the first four weeks of post-birth and then soon slows down significantly 
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[9]. 
 
1.3 Genetic dissection of the external ear 
1.3.1 Molecular genetics for the external ear in humans 
Most research on the human external ear always pays close attention to those with 
anomalies. According to Hunter’s standard, these anomalies are classified into three 
categories: (1) Grade I dysplasia: macrotia, absence or cleft in helix, lobular 
anomalies, and tragal anomalies. These patients have discernible ear structures and 
usually do not require the addition of skin or cartilage when surgical ear 
reconstruction is requested; (2) Grade II dysplasia: cup ear and mini ear. The external 
ear lacks one or more parts of the normal ear and reconstruction requires additional 
substitute skin and cartilage; (3) Grade III dysplasia: unilateral or bilateral microtia 
and anotia. In these cases, whole auricular parts of the ear are not observable, and 
total reconstruction is required [10]. 
Regarding the degree of surgical difficulty, a majority of research focused on 
external ear anomalies; e.g., microtia and anotia. Microtia prevalence rates range from 
0.83 to 17.4 per 10,000 births in Italy, France, Sweden, Finland and United States 
[11]. Such birth defects have a genetic or environmental predisposition. Some 
medication exposure in the gestational stages can cause microtia, such as retinoic acid, 
thalidomide and mycophenolate mofetil. Some genetic variants, like chromosomal 
abnormalities and missense/frameshift mutations have also been evidenced in some 
microtia-associated syndromes, as summarized in Table 1. 
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               Table 1. Human Disorders with Microtia 
Mutation Phenotype 
Autosomal trisomies 
Chromosome 13 [12] mental retardation, developmental delay, cleft palate, and ear anomalies 
Chromosome 18 [13] 
ear deformity, neonatal hypotony, high palate, microcephaly, 
brachydactyly, ventricular septal defect, and 5th finger clinodactyly 
Chromosome 22 [14] microtia, craniofacial dysmorphism, and polygyria 
Autosomal translocation 
6p24 [15] 
low set ears, developmental delay, frontal bossing, hypertelorism, flat, 
broad nasal bridge, and microretrognathia 
2q31.1 [16] 
malformed ears, malar and mandibular hypoplasia, lower lid 
coloboma, cleft palate, and conductive hearing loss 
Copy Number Variation 
4p16 [17] microtia, eye coloboma, and imperforation of nasolacrimal duct 
Single gene  
EYA1 [18, 19] 
branchio-oto-renal syndrome (microtia, branchial arch defects, hearing 
loss, and renal anomalies) 
FGF3 [20-22] hearing impairment and microtia 
GSC [23] bilateral congenital concha-type microtia 
HOXA1 [24] 
horizontal gaze abnormalities, cardiac autism, profound sensorineural 
hearing impairment and external ear defects 
HOXA2 [25] bilateral microtia 
SIX5 [26] microtia, branchial arch defects, hearing loss, and renal anomalies 
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1.3.2 Animal models for the external ear 
Mice are excellent models for dissecting the genetic basis of human ear growth and 
development. Twenty-seven genes were associated with external ear malformations 
by analyzing spontaneous mutant and conventional gene-targeting animals by 
Luquetti et al. [11]. Multi-functional growth factors, like Bmps and Fgfs, play a 
pivotal role in neuron and cartilage development and postnatal bone formation [27, 
28]. Bmp5 is related to external ear growth and spontaneous mutant mice have short 
ears [29]. Fgfr1 null embryos have marked reduction in the posterior axis and much 
smaller ears by regulating Hox gene activity [30]. The external ear of Fgf8 knockout 
newborns is abnormal or absent in line with having much smaller or fused first and 
second pharyngeal arches during embryonal development [31]. Wnt proteins are a 
group of secreted lipid-modified signaling proteins, which are involved in neural tube 
patterning. Wnt5a is expressed in mesenchymal cells of the ear and a loss-of-function 
mutation leads to outgrowth defects of the developing ears in mice [32]. 
 Besides growth factors, some key transcription factors are required at many 
stages of ear development and growth, including: cranial neural crest cells 
proliferation, differentiation, migration into the first and second branchial arches, and 
chondrocytic progenitor condensation. The HOX family is a critical regulator during 
the development of the second branchial arch, which contributes to the formation of 
the external and middle ear. Hoxa1 null mice show absent or hypoplastic external ears 
and abnormities of the middle and inner ear, whereas Hoxa1/Hoxb1 double mutants 
lack complete external ears [33]. Consistent with this, inactivating Hoxa2, Hoxa6, and 
Hoxb7 in mice also results in absent or hypoplastic ears [34]. Six1, Six4, and Six5 
have a remarkably overlapping expression in branchial arches; they are important 
transcription factors in normal neural crest development and skull formation [35]. 
Six1/Six4 double mutants develop microtia, yet single gene null mice have a normal 
phenotype. The Six-interacting protein Eya1 is also involved in ear formation. Eya1 
deficient mice show abnormalities in the external ear and branchial arch [36]. In 
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addition, two novel Eya1 interaction proteins, Sipl1 and Rbck1, enhance the function 
of Eya protein to act as co-activators for Six [37]. The knockdown of both Sipl1 and 
Rbck1 results in Eya null mice–like phenotype in zebrafish, characterized by specific 
abnormalities in branchial arch formation [37]. Tbx1, a T-box transcription factor, 
directly regulates Fgf8 expression. Tbx1 deficient mice show hypoplastic external 
ears, a similar phenotype compared to the Fgf8 mutants [38, 39]. Irf6 null embryo 
also lacks external ears accompanied by abnormal skin, limb, and craniofacial 
development [40]. 
In summary, the above-mentioned proteins related to ear growth always take part 
in the following steps: cranial neural crest patterning, the first and second branchial 
arches’ outgrowth, chondrocytic progenitor condensation, and cartilage formation. 
Furthermore, ear growth seems to be involved in several common signaling pathways. 
For example, 1) Tbx1 Fgf  Hox pathway: the upstream transcription factor Tbx1 
directly regulates growth factor Fgf expression, then Fgf controls the downstream 
proteins Hox’s activity. 2) Six -Eya -Sip1-Rbck1: Eya -Sip1 -Rbck1 forms a 
co-activator complex that regulates Six expression. 
 
1.3.3 Molecular genetics of the external ear in domestic animals 
In dogs, ear shape is a breed-defining trait. In 2010, Boyko et al. focused on this trait 
and identified a single region, CFA10: 10-11.6 Mb near MSRB3, which was 
associated with the ear shape of dogs (floppy, intermediate and prick) using 61,000 
SNPs in 915 individuals from 80 domestic breeds, 83 wild canids, and 10 outbred 
African shelter dogs [41]. Vaysse et al. also found the same ear shape region CFA10: 
9.5-11.5 Mb with a peak around 11.3-11.5 Mb, using 170,000 SNPs in 509 dogs from 
46 diverse breeds [42]. This region contained 287 SNPs or small indels, which were 
completely fixed in floppy-ear breeds. Twenty-five SNPs near three candidate genes 
WIF1, HMGA2, MSRB3 showed sequence conservation and therefore were promising 
positional candidates. 
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Although strong artificial selection also impels the rapid phenotypic evolution in 
pigs, a distinct morphology of ears seems to be influenced by multiple genes. This is 
in striking contrast to the findings in dogs where a couple of genes explain most of the 
phenotypic variance. Guo et al. firstly dissected the genetic basis of ear shape in pigs 
as early as 2004 [43]. They constructed a genetic linkage map using 175 markers and 
a reference pedigree, including 332 offspring from 19 hybrid Pietrain x (Pietrain x 
Hampshire) boars and 52 hybrid Leicoma x (Large White x Landrace) sows. Only one 
QTL was detected on SSC6 at the 1% genome-wide level with a 28.7 cM confidence 
interval (CI) using the least square regression method. 
In 1998, an F2 resource family derived from a cross between two divergent pig 
breeds—European Large White (small, erect ears) and Chinese Meishan (large, 
floppy ears) was created at the Roslin Institute (Edinburgh) [44]. Until 2007, Wei et al. 
divided ear size and erectness into three categories based on video images of 461 F2 
individuals recorded at 5–6 months of age [45]; for ear size: small, medium and large; 
for ear erectness: floppy, medium and prick. A linkage map was constructed with 152 
markers including 149 microsatellite markers and three type-I markers on 18 
autosomal chromosomes, which was used for the following genome scan. Significant 
QTLs were detected on SSC1, 5, 7, 9, and 12 for two traits using a web-based 
software，QTL EXPRESS. For erectness, the loci were located on SSC1, 5, and 7 at 
the 1% genome-wide level; while for ear size, two 1% genome-wide significant loci 
were mapped on SSC5 and 7. The QTL on SSC5 has only a 4 cM CI. By comparative 
mapping, they suggested GDF11 as a positional candidate gene, yet no further study 
was performed. 
From 2000 to 2006, a resource population was created by the interbreed of 
Chinese Erhualian (large, floppy ears) × American White Duroc (small, fully erect 
ears) in Nanchang (China). Ma et al. (2009) were the first to consider ear size as a 
quantitative trait [46]. They dissected both the left and right ears of 1029 F2 offspring 
at 240 days of age, drew each ear profile on a sulphate paper, scanned and then 
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calculated using the Leica Qwin area measurement software. Furthermore, more than 
1000 F2 pigs were also evaluated for ear erectness at 210 days of age. Twenty-three 
genome-wide and 12 suggestive QTLs were dissected using a genome-wide scan with 
194 microsatellites. The 1% genome-wide QTLs for erectness were detected on SSC1, 
2, 5, 7, 12, and 18, of which three QTLs on SSC1, 5, and 7 were consistent with the 
findings of Wei et al. [45]. Ear size and weight, which are highly correlated, shared 
common QTLs on SSC1, 4, 5, 7, 8, and 16 notably. The QTLs on SSC5 and SSC7 
explained more than 17% and 40% phenotypic variance, with 95% CI spanning 
around 10 cM and 3 cM, respectively. Both loci on SSC5 and SSC7 seemed to be the 
most promising targets for further fine-mapping. On this basis, Li et al. refined CI of 
the QTL on SSC5 to 8.7 cM by genotyping four additional markers in this F2 
population [47]. The CI was narrowed down to a small region harbouring three 
positional candidate genes：HMGA2, SOX5 and PTHLH. A HMGA2 SNP (JF748727: 
g.2836A>G) showed the strongest association with ear size in the F2 population and a 
synthetic commercial Sutai pig line; this gene was also a positional candidate for ear 
shape in dogs [42]. 
 
2 PPARD function 
PPARD is a member of the PPAR subfamily, which belongs to the 
steroid/thyroid/retinoid receptor superfamily [48]. The PPAR subfamily includes 
three isotypes, namely: α, β and γ, which share a similar common structure and 
mechanism of action as shown in Figure 2. PPAR and RXR form a functional 
heterodimer, which binds the PPAR response element (PPRE) in the promoter region 
of target genes [49]. Unliganded receptors remain inactivated; ligand binding changes 
conformation of the heterodimer, resulting in the release of co-repressors and the 
recruitment of co-activators necessary for transcription activation. Although the three 
isotypes share many similar characteristics, they have different tissue distribution, 
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ligand specificity and function. PPARG regulates fatty acid storage and glucose 
metabolism, is highly expressed in adipose tissue, and is a target for anti-diabetic 
drugs [50]. PPARA is a crucial regulator of fatty acid oxidation and is highly 
expressed in brown adipose tissue and liver [51]. PPARA is activated by 
adipose-derived fatty acids under nutrient deficient conditions. Activated PPARA 
up-regulates production of ketone bodies in the mitochondria of liver cells. PPARD is 
expressed ubiquitously and binds with endogenous ligands, such as fatty acids, 
triglyceride, prostacyclin, and retinoic acid [52-54]. A recent study showed that ice 
cream, butter, yogurt, and vegetable cream also increases PPARD activity, but not 
one common component was found to date [55]. PPARD plays a pivotal role in 
embryonic development, lipid metabolism, inflammatory response, wound healing, 
cancer and some basic cell activities, such as proliferation, differentiation, and 
survival. 
 
Figure 2. Mechanisms of transactivation. The PPAR/RXR heterodimer binds the 
PPRE in the promoter of target genes through the C domain (DNA-binding domain) 
of PPAR and RXR. Unliganded receptors remain inactivated; ligand binding by E/F 
domain (ligand-binding domain) activate the PPAR/RXR heterodimer, resulting in the 
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recruitment of cofactors containing histone acetyl-transferase activity, modifying 
nucleosome structure and contacting general transcription factors [56]. 
 
2.1 PPARD and metabolism 
PPARD knockout mice have a striking reduction in all types of adipose tissue, 
including gonadal, mesenteric, brown, and subcutaneous stores [57, 58]. However, 
adipose tissue-specific PPARD deficient mice do not show the similar phenotype as 
knockout mice [57]. Thus, reduced adiposity of knockout mice might reflect 
peripheral PPARD functions in systemic lipid metabolism, but not an intrinsic action 
within adipose tissue. In contrast, another study showed that constitutive activation of 
PPARD in adipose tissue improved long-chain fatty acid β-oxidation and energy 
dissipation, resulting in reduced adiposity [59]. Furthermore, transgenic 
adiposity-specific PPARD overexpressing mice were completely resistant to obesity 
and sensitive to insulin [59]. Activating PPARD with its ligands can reduce adiposity 
by controlling the expression of genes involved in fatty acid uptake, β-oxidation and 
energy uncoupling in adipose tissue of obese animals [60, 61]. Some lipolytic 
products can activate PPARD in brown adipocytes and elevate the expression of 
oxidative genes [62]. 
In addition, PPARD is also crucial in the control of fatty acid oxidation by 
regulating downstream target genes for fatty acid transport, β-oxidation, and 
mitochondrial respiration in skeletal muscle [63]. Transgenic mice overexpressing an 
activated form of PPARD in skeletal muscle produce more type I muscle fibres 
relative to wild type [64]. A high content of oxidative fibers can help mice to resist 
high-fat-induced obesity and glucose intolerance. Giordano et al. found that 
muscle-specific PPARD overexpression also resulted in increased myonuclear density, 
which was a characteristic response to exercise [65]. More importantly, PPARD has a 
potential to be a therapeutic target for Duchenne muscular dystrophy by treating its 
ligand [66]. 
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It is known that adipose tissue and skeletal muscle are important in metabolism. 
Skeletal muscle consumes glucose and lipid [67], while adipose tissue is not only for 
energy-storage but also acts as a major endocrine organ. Besides, the central nervous 
system (CNS) also plays an important role in regulating lipid metabolism. PPARD is 
expressed in CNS and is specifically enriched in the hypothalamus. Neuron-specific 
PPARD deficient mice exhibit elevated fat mass, decreased lean mass on a low-fat 
diet (LFD), leptin resistance, and hypothalamic inflammation [68]. 
In summary, activation of PPARD can prevent obesity and meliorate insulin 
resistance in adipose, muscle and CNS tissues. As a result, ligands of PPARD have 
been promising medicines to treat metabolic syndromes, obesity, and arteriosclerosis. 
PPARD is an important determinant of lipid metabolism, as described above. In 
pigs, over 90 QTLs for body fatness have been mapped on SSC7 containing PPARD 
according to pigQTLdb (http://www.animalgenome.org/). PPARD is the most 
promising positional and functional candidate for body fatness QTL on SSC7 by 
expression analysis in an F2 resource population created by crossing European Large 
White and Chinese Meishan [69]. An association study also showed that two 
haplotypes of PPARD were significantly associated with backfat thickness in F2 
animals of a Mangalitsa × Pietrain cross and a commercial German Landrace 
population, respectively [70]. PPARD was also identified as a functional candidate by 
comparing the expression profile between obese German Landrace and lean Pietrain 
[71]. 
 
2.2 PPARD and cell proliferation, differentiation, and apoptosis 
PPARD plays a pivotal role in cell proliferation, differentiation and apoptosis, as 
evidenced in animal models. PPARD null mice show abnormal placentas and smaller 
fetuses than controls [57, 58]. The main aberration of the placenta in PPARD 
deficient embryos appears in the giant cell layer; inactivation of PPARD inhibits 
differentiation of Rcho-1 trophoblast cells [72]. 
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PPARD deficient mice exhibit increased keratinocyte proliferation relative to 
controls in wound healing [73]. Consistent with this, a hyperproliferative reaction is 
associated with a higher expression of cell cycle proteins. A two-stage carcinogen 
bioassay induced a greater tumor size and more tumor multiplicity in PPARD null 
mice [74]. PPARD attenuated epithelial cell proliferation and tumor formation by 
upregulating its direct target gene ubiquitin C. The increased number of ubiquitin C 
enhanced turnover of PKCα, thus preventing further Raf1 and Mek/Erk pathways 
from increasing cell proliferation [75]. Di-Poi et al. found that PPARD could sense 
cytokines releasing from injured cells, upregulate its target genes Ilk/Pdk1 and 
downregulated Pten, and finally suppress keratinocyte apoptosis [76]. In addition, 
PPARD also ameliorated adhesion/migration of mature keratinocytes by increasing 
MMP9 levels [76]. 
PPARD is associated with intestinal tumorigenesis as shown in several studies. 
Harman et al. found that PPARD could attenuate colon polyp formation in both Min 
(Multiple Intestinal Neoplasia) mutants and chemically induced mouse models [77]. 
Consistent with this, ApcMin PPARD null mice are more susceptible to intestinal 
tumorigenesis than controls [78]. Furthermore, PPARD specific ligand treatment 
attenuates colon polyp multiplicity of mice [79]. In contrast, ApcMin mice harbour 
increased number and size of intestinal polyps on PPARD ligand treatment [80]. 
Unfortunately, no clear gene network has been dissected to date. 
Experimental data also supported that PPARD could regulate cell cycle and 
differentiation in different cell types [81]. PPARD can stimulate adipocyte 
differentiation and lipid accumulation by upregulating PPARG in adipose tissue 
[82-84], inhibit the differentiation of paneth cells by Indian hedgehog signal [85] and 
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2.3 PPARD and inflammation 
Inflammation is part of a complex biological response of vascular tissues to injury, 
microbial infections, and altered physiological conditions. PPARD is expressed in 
several inflammatory cells and closely connected with atherosclerosis [87]. PPARD 
ligands significantly repress atherosclerotic lesion formation in apoE-/- mice through 
an HDL-raising effect and anti-inflammatory activity [88]. Activated PPARD serves 
as a molecular brake in the inflammatory response by increasing the expression of IL1 
and Bcl6, reduces chemokine receptor signaling by upregulating RGSs (G 
protein-coupled signalings), and blocks cell migration and Tnfα shedding through 
raising Timp3 [88]. Yasunori et al. obtained a similar result, showing that the PPARD 
ligand increased the expression of Bcl6 and RGSs in an AngII -accelerated 
atherosclerosis model, characterized by increased vascular inflammatory response by 
repressing Bcl6 and RGSs [89]. PPARD also protects against dextran sodium 
sulfate-induced colitis by a ligand-independent mechanism [90]. 
Furthermore, PPARD represses immune inflammation in the central neural 
system [91]. In an experimental autoimmune encephalomyelitis model, PPARD 
deficient mice developed stronger inflammatory response as characterized by higher 
CD4+, IFNγ, and IL17 in the spinal cord than controls. 
Interestingly, macrophage activation also depends on PPARD. Th2 cytokines in 
adipocytes can activate its expression, which switches macrophage towards activation 
state M2 to prevent uncontrolled inflammation in white adipose tissue and liver [92]. 
ArgI, an M2 marker gene, seems to be a target of activated PPARD and PPARG in 
macrophages [93]. Consistent with these observations, bone marrow-specific PPARD 
deficient mice show insulin resistance, severe hepatosteatosis and increased adipocyte 
lipolysis. As a result, PPARD links lipid metabolism and immunity together. 
Besides macrophage polarization, PPARD exhibits another anti-inflammation 
role. The activated macrophages would rapidly engulf apoptotic cells in order to 
protect the body against autoimmune responses and the release of noxious cellular 
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contents. The process of uptaking apoptotic cells is delayed in PPARD null mice 
compared with wild type under ligand treatment [94]. This is partly due to a factor of 
the classical complement activation pathway, C1q, which is a direct target of PPARD. 
 
3 The function of A/B domain in PPARs 
3.1 Structure of PPARD 
Nuclear receptors are a group of transcription factors, which regulate the expression 
of downstream target genes. These factors share similar structures: the N-terminal 
A/B domain contains a ligand-independent activation function, the C-domain is 
responsible for DNA binding; the D-domain is a hinge region, and the E/F-domain 
takes charge of ligand-binding and ligand-independent activation function (Figure 2). 
Like most nuclear receptors, PPARs totally follow this structure. 
Among the four domains, the A/B domain is poorly conserved. Up to now, the 
crystallization of the A/B domain is impossible, demonstrating that it is intrinsically 
flexible [95]. Mutation analyses show that the region harbors conserved secondary 
structures [96]. The helix content in the A/B domain is important to PPARA 
transactivation as demonstrated by CD spectrum analysis [96]. The C/E domains are 
highly homologous among the three PPAR subtypes. The C domain contains two zinc 
finger motifs, while the E domain harbors several α-helices and β-sheets that form a 
large ligand-binding pocket [97]. The size and amino acid composition of the pocket 
mainly determines the ligand specificity [98]. Ligand binding alters the conformation 
of PPARs and switches them towards activation state. The F domain, namely AF-2, is 
also a part of the ligand binding domain (LBD). The AF-2 domain is an activation 
surface of PPARs, which contains a conserved helix 12 and additional parts of the 
LBD [99]. The helix 12 folds up against the core and forms a lid over the 
ligand-binding pocket. Its conformation is important for the receptor activation. 
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3.2 Modification of A/B domain regulates transcription activity 
PPARs are phosphoproteins whose function can be turned on or off by 
phosphorylation of serine, threonine or tyrosine residues. The phosphorylation and 
dephosphorylation of proteins are important molecular switches, which enable cells to 
give an expeditious response to environmental change. As mentioned above, PPARG 
is an important regulator of fatty acid storage and glucose metabolism with a high 
sensitivity to insulin. Insulin is an activator of MAPK, which can phosphorylate the 
A/B domain of human PPARG (hPPARG) at serine 112 [100]. Phosphorylated 
PPARG has a reduced transcription activity to downstream target genes that stimulate 
lipid uptake and adipogenesis. If phosphorylation of hPPARG is artificially prevented 
by transiting serine into alanine, mice do not show increased adiposity, but are 
protected from insulin resistance on high-fat diets [101]. Furthermore, insulin 
treatment also stimulates hPPARA phosphorylation at serine 12 and serine 21 in the 
A/B domain and increases its transcription activity [102]. Cellular stress in the heart 
can also activate phosphorylation of hPPARA along with phosphosites by MAPK 
pathway at the same time [103]. Several additional PPAR kinases are known that 
directly act on these receptors as summarized by Katherine et al. [104]. PPARs’ 
phosphorylation in the A/B domain also seems to be a regulator for subcellular 
localization. PPARG phosphorylation at serine 16 and serine 21 by CK-II can 
stimulate CRM1/Ran/RanBP3-mediated PPARG export from the nucleus [105]. 
Ubiquitination is an additional biochemical mechanism that regulates PPAR 
activity. The process links ubiquitins to some specific lysine residues of the target 
proteins mediated by a series of enzymes. There are three types of ubiquitination 
patterns, including polyubiquitination linked via lysine 48 or lysine 63 of ubiquitin, 
monoubiquitination. The canonical ubiquitin chains, linked by their own lysine 48, 
are a degradation signal of substrates by 26S proteasome. The other two play wider 
roles in cellular functions such as translation, cell cycle regulation and protein-protein 
interactions [106, 107]. An E3 ubiquitin ligase, MDM2, can interact with PPARA 
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through the A/B domain [108]. MDM2 overexpression increases hPPARA 
ubiquitination and thereby decreases its protein level. MDM2 can also regulate 
transcription activity of PPARA. For example, if the ratio of MDM2 to PPARA is < 1, 
then PPARA activity is increased while a ratio > 1 inhibits its activity in response to 
the ligand. Regardless of the amount of ligands, the degradation of PPARA usually 
can be rescued by bound ligands [109]. However, unlike PPARA, hPPARG protein 
levels are significantly reduced in adipocytes and fibroblasts in the presence of 
specific ligands [110]. Interestingly, the degradation of PPARG is essential for its 
transcription activity mediated by ligands in adipose cells. In 2012, a mysterious 
ubiquitin ligase was identified as SIAH2, regulating ligand-dependent activation by 
linking polyubiquitin chains with hPPARG [111]. Phosphorylated A/B domain of 
hPPARG leads to reduced transcription activity, which might be partly due to a 
decreased degradation by the ubiquitin proteasome system. Fujimoto et al. confirmed 
the hypothesis that Pin1 inhibits binding of ubiquitin ligases by directly interacting 
with the phosphorylated A/B domain [112]. To date, ubiquitination might be the only 
posttranslational modification of PPARD. Like in PPARA, ligands also prevent 
ubiquitination and subsequent degradation of PPARD in U2OS cells [113]. However, 
another study showed that protein levels of PPARD in mouse fibroblasts are a 
determiner to ligand-dependent ubiquitination and degradation pattern [114]. 
Besides the above modifications, SUMOylation is also a posttranslational 
regulator of PPAR activity. Like ubiquitin, small ubiquitin-like modifier (SUMO) 
proteins are also covalently attached to K residues in the consensus site ψKX(D/E) of 
target proteins by a series of enzymes in cells to modulate their functions. SUMO is 
involved in several cellular processes, such as protein stability, transcription 
regulation, and nuclear-cytosolic transport [115]. It has been shown that 
SUMOylation of PPARA can repress gene expression at cellular and physiological 
levels. hPPARA can link a SUMO at K185 mediated by E2-conjugating enzyme 
UBC9 and SUMO E3-ligase PIASy in COS-7 cells and human hepatoma cells, 
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thereby downregulating its transcription activity through specific recruitment of 
corepressor NCoR [116]. Posttranslational SUMOylation of PPARA also plays a key 
role in repressing genes expression involved in hepatic steroid synthesis and 
complement system of mouse liver in a sex-dependent manner [117]. In females, 
PPARA with a SUMO at K358 in the E/F domain acts as a transrepressor, interacting 
with a transcription factor GABPα bound to CYP7B1 gene promoter [117, 118]. This 
complex triggers recruitment of histone deacetylase and histone methylases, thereby 
methylating adjacent Sp1 and histones. These events block CYP7B1 expression, 
which protects females against estrogen-induced intrahepatic cholestasis, a common 
hepatic disease during pregnancy [117]. Interestingly, the K358-SUMOylated 
PPARA does not bind with its functional element PPRE, but forms a complex with 
GABPα [117]. The transcription activity of PPARG can also be repressed by 
SUMOylation. PPARG1 can be modified by SUMO-1 at K107 in the A/B domain 
[119]. A site-mutagenesis assay showed that the loss of SUMOylation enhanced 
target gene expression in HEK293 cells [119]. Consistent results have been obtained 
with a PPARG1 K107R mutant exhibiting an increased transcription activity of the 
PPRE promoter region compared with a wild type in NIH3T3 cells using a luciferase 
reporter assay [119, 120]. Floyd et al. unveiled the potential mechanism on 
SUMOylation-dependent repression [121]. They found that the covalently bound 
SUMO peptide affected stability and transcription activity of PPARG1 instead of its 
nuclear localization [121]. PPARG also harbors another SUMO site K365, which is a 
determinant to transrepression of inflammatory responses in mouse macrophages 
[122]. The initial step of the response pathway is SUMOylation at K365 in the E/F 
domain in the presence of ligands [122]. This modification turns off the expression of 
inflammatory response genes due to the new conformation preventing the interaction 
between PPARG and 19S proteasome [122]. In contrast, the activation function of the 
ligand has been blocked by this SUMO peptide that promotes recruitment of 
corepressor NCOR-HDAC3 complexes [122]. 
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4 SOX9 function 
SOX9 is a transcription factor, which binds to the motif CCTTGAG together with 
other members of the HMG-box class DNA binding proteins. It plays a crucial role in 
chondrogenesis, sex determination, cancer and organ maintenance [123-126]. Here I 
will focus on its function in chondrogenesis. 
Chondrogenesis is a multistep process that begins with the condensation of 
mesenchymal progenitor cells. These cells differentiate into chondrocytes, which 
proliferate and produce a cartilage extracellular matrix to prefigure the future shape of 
endochondral bones. At the initial differentiation stage, highly proliferative round 
chondrocytes are present, which are followed by slowly proliferative flat 
chondrocytes. Then the chondrocytes gradually exit the cell cycle and differentiate 
into prehypertrophic and subsequently hypertrophic chondrocytes. Finally, mature 
hypertrophic chondrocytes go through apoptosis [127]. 
SOX9 is an evolutionarily conserved transcription regulator in chondrogenesis. 
Its expression level is high in mesenchymal progenitors and proliferating 
chondrocytes, and declines abruptly in prehypertrophic chondrocytes. Such 
expression patterns are strict in every stage of bone development as studied in mice: (i) 
in mesenchymal progenitors, the miss-expression of Sox9 results in disordered 
mesenchymal condensation, ectopic chondrogenesis and final limb bud development 
[128]; (ii) in proliferating chondrocytes, inactivation causes chondrocyte apoptosis 
and terminal maturation, skipping from the intermediate hypertrophy stage [127]; (iii) 
in hypertrophic chondrocytes, overexpression retards vascularization, bone marrow 
formation, and endochondral ossification [129]. 
Mutations in and around SOX9 also result in skeletal malformations in humans. 
Several missense and frameshift mutations cause campomelic dysplasia, characterized 
by the bowing of the femur and tibia [130]. Some regulatory mutations result in the 
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disruption of normal bone growth and development; i.e., patients with Cooks 
Syndrome carry microduplications upstream SOX9 overlapping a critical 1.2 Mb 
interval [131]. In Pierre Robin sequence, translocation breakpoints flanking SOX9 
have been described [132].  
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The pinna refers to the visible section of an animal’s ear, and serves several functions, 
including: collecting sounds, radiating heat and signaling mood. The structure itself is 
important in identification as well: for example, the size of the pinna is a significant 
conformation that distinguishes certain pig breeds. In humans, defects in the pinna are 
quite common; for instance, microtia, which is characterized by a small and 
abnormally shaped pinna, has a high prevalence, ranging from 0.83 to 17.4 per 10,000 
births internationally. However, only a minority of genetic or environmental causes 
have been found for this prevalence to date. Long selective breeding has created 
obvious diversities in pinna size among domesticated pigs, indicating a potential 
model to explain pinna deformity in humans. However, because of a complex genetic 
background behind quantitative traits, to definitively identify the causative mutation 
in pigs has not had much success in the past several decades.  
To identify the genes that control pinna size, Ma et al. performed a genome scan 
in a large White Duroc x Erhualian pig resource family and mapped a 1% 
genome-wide QTL to a 2 cM confidence interval on chromosome 7 [1]. In this thesis, 
my all studies focused on dissection of the molecular basis on the QTL. In chapter 2, 
we further fine-mapped the QTL and finally identified that a missense mutation 
PPARD G32E could in fact cause such major QTL effects on the pinna size in pigs on 
a genetic level [2]. This is the first time a study has discovered a novel function of 
PPARD on controlling pinna size. However, limited knowledge of the PPARD causal 
mutation indicated that the functional analysis of the mutation was essential in 
identifying how it controls pinna development. In chapter 3, we investigated the 
contribution of the G32E substitution to the transcription activity of porcine PPARD 
and deciphered the underlying molecular mechanism involved. We found that the 
substitution was a loss-of-function mutation that reduced transcription activity of 
PPARD by promoting nuclear export and changing non-proteolytic ubiquitination [3]. 
The overexpression of the G32E mutant reduced SOX9 expression, which is a key 
regulator for all chondrocyte development. In chapter 4, we conducted a function 
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analysis for an 18-bp insertion/deletion in the 5’-untranslated region (UTR) of SOX9 
when we identified the indel in three pig breeds, including Laiwu, Bamei and Large 
White. The 18-bp was indispensable to the translation of SOX9; the deletion 
significantly reduced translation efficiency and caused mRNA destability [4]. 
However, it was not associated with pinna size in the White Duroc x Erhualian 
population. These findings established an essential basis for the future research on 
how PPARD controls pinna development.  
 
1 To dissect the genetic basis of ear size in pigs 
1.1 Current research strategy 
If we look back on the published data on external ear studies in pigs, it is evident that 
they all follow a very similar research strategy (see Figure 1): first, a linkage map was 
constructed using over one hundred microsatellite markers covering the whole 
genome and pedigree information. Second, all traits of interest were measured in F2 
offspring. Finally, some specific loci were identified, combining the following 
information including a linkage map, microsatellite genotypes and phenotypic values. 
The CI of QTL typically spans more than 20 cM (approx. 2.0 x 107 bp). The 
subsequent fine-mapping step is necessary to identify the quantitative trait nucleotides 
(QTN). The mapping strategy has to consider marker density, crossover density, QTL 
detectability and molecular architecture as described by Georges [5]. Therefore, QTLs 
explaining a large fraction of phenotypic variation in large populations are very good 
candidates for fine-mapping. To determine the exact location of a QTL, the first step 
is to enhance the map resolution by adding more markers in the CI. Based on 
sequences in the Ensembl project, NCBI and UCSC databases, novel markers can be 
identified in the specific regions [6]. A high-resolution identical-by-descent (IBD) 
mapping is followed by linkage and linkage-disequilibrium analysis. The QTL 
genotype of F1 boars and sows can be deduced by genetic markers and phenotype 
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segregation in their F2 offspring using linkage analysis. The shared IBD interval can 
be determined among F1 animals carrying the known QTL genotype [7]. To obtain a 
high enough resolution map for identifying a causative gene, denser genetic markers 
and more chromosomes carrying the relevant alleles are required, as described; for 
instance, for the identification of IGF2 [8]. A promising positional candidate gene 
may be chosen according to accumulating functional research of the genes in humans 
and mice [9]. Then, causative mutations in a candidate gene might be obtained. 
 
Figure 1. General strategy for QTL identification in pigs  
 
1.2 Progress on genetic research strategy for pigs 
The pig genome has been sequenced using a clone-by-clone sequencing strategy by 
the Wellcome Trust Sanger Institute, which began in 2005 [9]. The increasing number 
of published sequences makes the development of new markers no longer a tedious 
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and time-consuming effort. High-density markers in the genome are easily achieved; 
however, traditional linkage analysis only uses intergenerational recombination events 
in resource populations. As a result, a large quantity of markers has a limited effect on 
improving QTL mapping. More precise analysis might be linkage disequilibrium and 
association analysis, which are based on a phenomenon that LD decays quickly when 
the marker is far away from the QTL [10]. LD is caused by historical events that 
chromosomal segments inherited from a common ancestor that became shorter as 
generation recombination occurred. As a result, the history of domestication and the 
breed determine its LD pattern and mapping resolution. In European breeds, the 
extent of LD is large—up to 400 kb, whereas in Chinese breeds LD extends generally 
less than 10 kb. The LD of European wild boar is intermediate between Chinese and 
European breeds [11]. Consistent with this, SNP spacing should be about 0.1 cM for 
European breeds and 0.006 cM for Chinese breeds. Therefore, to develop 30k and 
500k SNPs per individual is required in European and Chinese pigs [11]. 
In January 2009, Illumina launched the PorcineSNP60 BeadChip that included 
65,000 evenly spaced probes, which were sufficient for whole-genome association 
studies, determination of genetic merit, identification of QTL, and comparative 
genetic studies. The BeadChip presented genetic variation in four main commercial 
porcine breeds, including Duroc, Landrace, Pietrain and Large White. Since the 
BeadChip was available, the mapping strategy of quantitative traits changed quickly 
[12-15]. 
GWAS is a strategy to detect the statistical association between a trait and a 
genome-wide panel of markers. Both LD and linkage influence observed associations. 
So GWAS is effective in identifying loci for complex traits in a large number of 
individuals in a commercial breed if the existing 60k Chip is used. However, a higher 
resolution marker panel is required if GWAS is used for the comparative analysis of 
several breeds due to a small LD between breeds. Furthermore, the statistical 
formulas have to take population stratification effects and kin structures of the 
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population into consideration. As a result, a large number of samples might be 
required to get an accurate QTL. For example, if we identify QTLs for a trait with a 
heredity capacity of 0.25 and r2=0.5 using GWAS, over 1,800 animals are necessary 
to detect the QTL, explaining < 4% genetic variance [10]. It might be better to 
confirm the results in a large sample of the same breed [10]. These loci can be applied 
in the future breeding for the same breed. Although the PorcineSNP60 BeadChip has 
no sufficient markers to detect some Chinese breeds, it is effective to detect a QTL by 
combining several F2 resource families created by the same founder breeds. 
The second and next-generation sequencing methods were introduced in 2007 
and 2011, respectively. The new methods provide cheap, efficient, and reliable 
large-scale DNA sequencing. Groenen et al. found that genes involved in RNA 
splicing and decay were selected in domestic history using a selective sweep analysis 
[16]. Rubin et al. reported that three loci associated with NR6A1, PLAG1 and LCORL 
explained most of the phenotypic variation of elongation of the backs and an 
increased number of vertebrae in domestic European pigs [17]. These pioneering 
studies indicated that (1) selective sweep analysis was a promising method to identify 
QTL, (2) whole-genome sequencing resulted in numerous new markers for future 
higher resolution PorcineSNP BeadChips, and (3) a large number of non-synonymous 
substitutions in domestic pigs were very useful resources for the future identification 
of QTN. 
The above studies only focused on the association between DNA sequence 
variants and phenotype; however, they all omitted intermediate steps of genetic 
information flow. Using next-generation sequencing technology, some studies began 
to analyze quantitative trait transcripts and used system genetics approaches to 
identify QTG or QTN Identification [18-20]. System genetics usually include: (1) 
identification of the eQTL by calculating the association between transcript 
abundance and DNA variants; (2) identification of the QTT by analyzing the 
association between transcript abundance and phenotypic values; (3) construction of a 
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co-expression network of relevant transcripts that are associated with both molecular 
variant and phenotype; (4) identification of a QTG or QTN by combining the results 
of eQTL, QTT, and co-expression network [21]. To date, no QTN has been detected 
using system genetics in domestic animals. Excitingly, two studies of body weight 
and obesity in mice and humans showed a strong level of system genetics to detect the 
biological basis of variation for quantitative traits [22, 23]. 
These emerging methods in identifying the molecular mechanisms of complex 
traits- including ear traits - in pigs is underway. 
 
2 To dissect biological function of causative mutations 
When a potential causative mutation is identified, a functional confirmatory 
experiment has to follow to reveal its biological function. Furthermore, functional 
experiments are also effective to exclude those nonfunctional variants in the refined 
region. Types of genetic variation include SNPs, insertion/deletion, duplication and 
inversion. Here I give some examples to describe the usual methods to dissect 
biological functions for different types of variation. 
 
2.1 SNP 
There are numerous SNPs in the whole genome. Here we divide SNPs into 2 groups 
including protein-coding and regulatory mutation. To a mutation in the protein-coding 
region, the first thing is to prove the mutation is associated with the interested traits. A 
nonconservative substitution (R200Q) in 5'-AMP-activated protein kinase subunit 
gamma-3 gene (PRKAG3) caused high glycogen content in skeletal muscle of 
Hamphshire pigs [24]. Milan et al. found that loss-of-function in the homologous 
gene in yeast resulted in defects in glucose metabolism and less glycogen storage [24]. 
However, in their original paper, no evidence proved the function of alkaline arginine 
to neutral glutamine substitution at position 200 (R200Q) in PRKAG3. Then they 
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made 2 transgenic mice overexpressing wild type PRKAG3 or R225Q mutant subunit 
and knockout mice [25]. They found that the mutation was gain-of-function whose 
transgenic mice showed a marked increase in glycogen content[25]. To SNPs in 
introns, the most important thing is to find whether the mutation affect gene 
expression. In 2003, the first QTN was identified as a G3072A substitution in intron 3 
of IGF2 [8]. They found that the mutation located in a functional element by EMSA 
and could increase IGF2 expression by a luciferase reporter assay. Using 
oligonucleotide capture and mass spectrometry, researchers found that the function 
element could be bound by a repressor ZBED6 [26]. To mutations in UTR, the 
efficient experiment is to confirm whether and how the mutation affects RNA 
stability and translation efficiency. A G to A transition in the 3’-UTR of GDF8 gene 
creates a target site for mir1 and mir206 [27]. By luciferase reporter assay, they found 
mir1 and mir206 inhibited GDF8 translation and hence caused muscular hypertrophy 
of Texel sheep [27]. No study describes the causative mutation in the 5’-UTR. 
 
2.2 Chromosomal rearrangement 
Another type of genetic variant is commonly chromosomal rearrangement including 
deletion, duplication, inversion and translocation. Usually, this type of mutation in the 
protein-coding region does not need to do additional functional experiments. However, 
if the mutation locates in intron, its function has to be elucidated. The horse graying 
with age is caused by a 4.6-kb duplication in the sixth intron of STX17 gene [28]. The 
duplication increases the expression of two neighboring genes STX17 and NR4A3 in 
melanoma by RT-qPCR. [28]. The two copies are strongly associated with increased 
expression in neural crest-derived cells, which are precursors of melanocytes in 
vertebrates. Pea-comb of Chicken is caused by a massive amplification of a 
duplicated sequence in the first intron of SOX5 [29]. The expression of SOX5 was 
investigated in both Pea-comb and wild-type embryos during development by 
immunohistochemical staining and situ-hybridization. Pea-comb embryos showed a 
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strikingly high SOX5 expression in mesenchymal cells located beneath the surface 
ectoderm where the comb and wattles develop [29]. Both above examples are 
classical functional elements duplication. Sometimes some simple repeat elements 
might repress or activate gene expression on more complex conditions. The CGG 
expansion might be abnormally modified by methylation which lead to chromatin 
condensation and repress neighboring gene expression [30]. Furthermore, the GAA 
repeats are prone to form nonusual B-DNA structure and heterochromatin that lead to 
a direct transcriptional silencing [31]. In our case, the 18-bp deletion locates in the 
5’-UTR of porcine SOX9 which reduces translational efficiency due to rapid RNA 
decay.  
 
3 The pig is a potential biomedical model for ear size 
The availability of a whole genome sequence of the pig makes it a promising large 
animal model for human diseases because the two species share similar size, anatomy, 
and physiology. The pig has undergone intense selection pressures, causing 
differentiated subpopulations and phenotypes. The genetic dissection of extreme 
phenotypes is not so difficult and time-consuming today with the availability of new 
sequencing technologies and marker genotyping tools in the last two decades. Today, 
the pig model has been developed for some human diseases, including Alzheimer’s, 
cancer, and muscular dystrophy. Recently, it has been reported that 112 new gene 
variants might be models for human diseases by sequencing several strains of wild 
boars and domestic pigs [32]. Hence, it is reasonable to expect that more new 
causative genes for ear size will be identified in the future. 
 
4 Future prospect 
 Although we have already known that PPARD G32E is a loss-of-function mutation, 
how the variant leads to rapidly increased ear size is still unclear. The studies on 
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Hoxa2 might be the pioneer to dissect molecular basis of microtia/ anotia genes in 
mice. As we known, Hoxa2 is a key transcription factor, which regulates the 
expression of target genes for formation of ear in the second branchial arch. Deficient 
Hoxa2 causes anotia and abnormality of the middle ear. The well-annotated whole 
genome sequence and next-generation sequencing technology provide unique 
opportunity to dissect how this transcription factor controls outer ear development in 
embryonic stage. Donaldson et al. used chromatin immunoprecipitation and 
sequencing (ChIP-seq) to identify binding sites of Hoxa2 in whole genome at 
Embryonic Day 11.5 of mouse [33]. This study confirmed previous findings that 
Hoxa2 activated the following target genes Robo2, Six2, Runx2, Msx1, Meis1, and 
Meis2, of which Six2 had been evidenced to involve in outer ear development in mice 
[34-39]. Furthermore, they first reported that Hoxa2 regulated gene expression within 
Wnt-β-catenin signaling pathway including a well-known small ear gene Wnt5a [33]. 
Interestingly, Hoxa2 inactivation causes anotia, while some of its target genes null 
mice show microtia. This study indicates ChIP-seq is a simple but very effective 
method to dissect the mechanism of transcription factors.  
 As expected and excitingly, next-generation sequencing technology and 
PorcineSNP60 BeadChip had accelerated genetic dissection in pigs. However, most 
studies on molecular mechanism of growth and development were carried out in mice 
or simpler animal models. Here we are planning to identify molecular basis behind 
PPARD G32E, which cause increased ear size. In chapter 3, we have known that the 
nonconservative G32E substitution reduced its transcriptional activity by nuclear 
export and posttranslational modification. Mutant has less effective quantity of 
nucleus PPARD than wild type. It indicates that some different target genes between 
mutant and wild type can be identified using Chip-Seq. So we are planning to do a 
Chip-seq of PPARD in ears of Erhualian (mutant) and western commercial pigs (wild 
type) to identify binding sites of PPARD and detect different sites between both pigs. 
Furthermore, it also needs to elucidate how transcription activity of target genes is 
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controlled by PPARD. Some target genes involved in cell growth pathway or ear 
development pathway might be candidate for the following RT-PCR. Because the 
activation of PPARD is ligand-dependent [40], it might be effective to detect different 
expression of candidate genes identified in the ChIP-Seq between with and without 
ligand treatment in cultured primary ear chondrocyte isolated from Erhualian and 
western commercial pigs. By this way, we can know which genes in ChIP-Seq can be 
activated by PPARD. And the significant difference needs to be confirmed again in 
ear cartilage of wild type and mutant in a large number. PPARD specific ligand 
GW0742 inhibits the growth of primary ear chondrocytes of western commercial pigs. 
So we hope to identify a gene to satisfy the following hypothesis: (1) its quantity of 
binding site in ChIP-Seq is distinct between wild type and mutant; (2) its transcript 
can be activated by the specific ligand of PPARD in the primary ear chondrocytes of 
western commercial pigs but not in chondrocyte of Erhualian; (3) expression 
distinction should be detected in pigs ear cartilage between Erhualian and western 
commercial pigs; (4) the activity of some cell growth markers controlled by the 
identified gene would be different in pig ear cartilage between Erhualian and western 
commercial pigs.  
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